FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225536357> ?p ?o ?g. }

• W4225536357 endingPage "2285" @default.
• W4225536357 startingPage "2275" @default.
• W4225536357 abstract "The aim of this study was to examine the value of first-phase ejection fraction (EF1), to predict response to cardiac resynchronization therapy (CRT) and clinical outcomes after CRT. CRT is an important treatment for patients with chronic heart failure. However, even in carefully selected cases, up to 40% of patients fail to respond. EF1, the ejection fraction up to the time of maximal ventricular contraction, is a novel sensitive echocardiographic measure of early systolic function and might relate to response to CRT. An initial retrospective study was performed in 197 patients who underwent CRT between 2009 and 2018 and were followed to determine clinical outcomes at King’s Health Partners in London. A validation study (n = 100) was performed in patients undergoing CRT at Barts Heart Centre in London. Volumetric response rate (reduction in end-systolic volume ≥15%) was 92.3% and 12.1% for those with EF1 in the highest and lowest tertiles (P < 0.001). A cutoff value of 11.9% for EF1 had >85% sensitivity and specificity for prediction of response to CRT; on multivariate binary logistic regression analysis incorporating previously defined predictors, EF1 was the strongest predictor of response (odds ratio [OR]: 1.56 per 1% change in EF1; 95% CI: 1.37-1.78; P < 0.001). EF1 was also the strongest predictor of improvement in clinical composite score (OR: 1.11; 95% CI: 1.04-1.19; P = 0.001). Improvement in EF1 at 6 months after CRT implantation (6.5% ± 5.8% vs 1.8% ± 4.3% in responders vs nonresponders; P < 0.001) was the best predictor of heart failure rehospitalization and death after median follow-up period of 20.3 months (HR: 0.81; 95% CI: 0.73-0.90; P < 0.001). In the validation cohort, EF1 was a similarly 1strong predictor of response (OR: 1.45; 95% CI: 1.23-1.70; P < 0.001) as in the original cohort. EF1 is a promising marker to identify patients likely to respond to CRT." @default.
• W4225536357 created "2022-05-05" @default.
• W4225536357 creator A5002124380 @default.
• W4225536357 creator A5003044904 @default.
• W4225536357 creator A5017474315 @default.
• W4225536357 creator A5024915207 @default.
• W4225536357 creator A5029460921 @default.
• W4225536357 creator A5039500853 @default.
• W4225536357 creator A5056362398 @default.
• W4225536357 creator A5057144324 @default.
• W4225536357 creator A5069248283 @default.
• W4225536357 creator A5069589628 @default.
• W4225536357 creator A5075056333 @default.
• W4225536357 creator A5078754152 @default.
• W4225536357 creator A5090768352 @default.
• W4225536357 date "2021-12-01" @default.
• W4225536357 modified "2023-10-15" @default.
• W4225536357 title "First-Phase Ejection Fraction Predicts Response to Cardiac Resynchronization Therapy and Adverse Outcomes" @default.
• W4225536357 cites W1952743273 @default.
• W4225536357 cites W1989555111 @default.
• W4225536357 cites W2025139676 @default.
• W4225536357 cites W2065006376 @default.
• W4225536357 cites W2065945049 @default.
• W4225536357 cites W2071450549 @default.
• W4225536357 cites W2100056258 @default.
• W4225536357 cites W2120043151 @default.
• W4225536357 cites W2122494139 @default.
• W4225536357 cites W2140652967 @default.
• W4225536357 cites W2174325278 @default.
• W4225536357 cites W2191896778 @default.
• W4225536357 cites W2522819610 @default.
• W4225536357 cites W2590732834 @default.
• W4225536357 cites W2590750907 @default.
• W4225536357 cites W2609605008 @default.
• W4225536357 cites W2816686836 @default.
• W4225536357 cites W2901908006 @default.
• W4225536357 cites W3017780160 @default.
• W4225536357 cites W3022179669 @default.
• W4225536357 cites W3049190643 @default.
• W4225536357 cites W4211125439 @default.
• W4225536357 cites W4249896096 @default.
• W4225536357 cites W4293860347 @default.
• W4225536357 cites W99112280 @default.
• W4225536357 doi "https://doi.org/10.1016/j.jcmg.2021.05.007" @default.
• W4225536357 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34886993" @default.
• W4225536357 hasPublicationYear "2021" @default.
• W4225536357 type Work @default.
• W4225536357 citedByCount "4" @default.
• W4225536357 countsByYear W42255363572021 @default.
• W4225536357 countsByYear W42255363572022 @default.
• W4225536357 countsByYear W42255363572023 @default.
• W4225536357 crossrefType "journal-article" @default.
• W4225536357 hasAuthorship W4225536357A5002124380 @default.
• W4225536357 hasAuthorship W4225536357A5003044904 @default.
• W4225536357 hasAuthorship W4225536357A5017474315 @default.
• W4225536357 hasAuthorship W4225536357A5024915207 @default.
• W4225536357 hasAuthorship W4225536357A5029460921 @default.
• W4225536357 hasAuthorship W4225536357A5039500853 @default.
• W4225536357 hasAuthorship W4225536357A5056362398 @default.
• W4225536357 hasAuthorship W4225536357A5057144324 @default.
• W4225536357 hasAuthorship W4225536357A5069248283 @default.
• W4225536357 hasAuthorship W4225536357A5069589628 @default.
• W4225536357 hasAuthorship W4225536357A5075056333 @default.
• W4225536357 hasAuthorship W4225536357A5078754152 @default.
• W4225536357 hasAuthorship W4225536357A5090768352 @default.
• W4225536357 hasConcept C121332964 @default.
• W4225536357 hasConcept C126322002 @default.
• W4225536357 hasConcept C151956035 @default.
• W4225536357 hasConcept C156957248 @default.
• W4225536357 hasConcept C164705383 @default.
• W4225536357 hasConcept C167135981 @default.
• W4225536357 hasConcept C2776034619 @default.
• W4225536357 hasConcept C2778198053 @default.
• W4225536357 hasConcept C2778217198 @default.
• W4225536357 hasConcept C38180746 @default.
• W4225536357 hasConcept C62520636 @default.
• W4225536357 hasConcept C71924100 @default.
• W4225536357 hasConcept C78085059 @default.
• W4225536357 hasConcept C80461066 @default.
• W4225536357 hasConceptScore W4225536357C121332964 @default.
• W4225536357 hasConceptScore W4225536357C126322002 @default.
• W4225536357 hasConceptScore W4225536357C151956035 @default.
• W4225536357 hasConceptScore W4225536357C156957248 @default.
• W4225536357 hasConceptScore W4225536357C164705383 @default.
• W4225536357 hasConceptScore W4225536357C167135981 @default.
• W4225536357 hasConceptScore W4225536357C2776034619 @default.
• W4225536357 hasConceptScore W4225536357C2778198053 @default.
• W4225536357 hasConceptScore W4225536357C2778217198 @default.
• W4225536357 hasConceptScore W4225536357C38180746 @default.
• W4225536357 hasConceptScore W4225536357C62520636 @default.
• W4225536357 hasConceptScore W4225536357C71924100 @default.
• W4225536357 hasConceptScore W4225536357C78085059 @default.
• W4225536357 hasConceptScore W4225536357C80461066 @default.
• W4225536357 hasIssue "12" @default.
• W4225536357 hasLocation W42255363571 @default.
• W4225536357 hasLocation W42255363572 @default.
• W4225536357 hasOpenAccess W4225536357 @default.
• W4225536357 hasPrimaryLocation W42255363571 @default.

• next